Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil, cyclosporine A and SDZ PSC 833 in dependence on extracellular pH. 1994

J Zacherl, and G Hamilton, and T Thalhammer, and M Riegler, and E P Cosentini, and A Ellinger, and G Bischof, and M Schweitzer, and B Teleky, and T Koperna
I. Department of Surgery, University of Vienna, Austria.

The ability of the multidrug resistance modifiers R- and R,S-verapamil (VPL), cyclosporine A (CsA) and its non-immunosuppressive derivative SDZ PSC 833 (PSC 833) to inhibit P-glycoprotein (P-gp)-mediated transepithelial flux of tritiated vinblastine was investigated using tight and highly resistant (R > 1,400 omega cm2) monolayer cultures of intestinal adenocarcinoma-derived HCT-8 cells grown on permeable tissue-culture inserts. Apical addition of these chemosensitizers inhibited drug flux (137 pmol h-1 cm-2; range, 133-142 pmol h-1 cm-2) in the basal to apical secretory direction at clinically relevant concentrations, with PSC 833 showing the highest activity, exhibiting inhibition at concentrations as low as 10 ng/ml (9 nM). Acidification of the modulator-containing apical compartment to an extracellular pH (pHo) of 6.8 had no influence on MDR reversal by CsA at 1 microgram/ml (0.9 microM; flux inhibition, 52%) or by PSC 833 at 100 ng/ml (0.09 microM; flux inhibition, 60%), in contrast to R,S- and R-VPL, which showed decreased inhibition and caused less accumulation of vinblastine in HCT-8 cells under this condition (flux inhibition of 35% and 23%, respectively, at pHo 6.8 vs 50% and 43%, respectively, at pHo 7.5). P-gp-mediated rhodamine 123 efflux from dye-loaded single-cell suspensions of HCT-8 cells as measured by flow cytometry was not impeded at pHo 6.8 in comparison with pHo 7.5 in standard medium, but at low pHo the inhibitory activity of R-VPL (29% vs 60% rhodamine 123 efflux inhibition) was diminished significantly, again without a reduction in the effect of PSC 833 (rhodamine 123 flux inhibition, 75%). In conclusion, drug extrusion across polarised monolayers, which offer a relevant model for normal epithelia and tumour border areas, is inhibited by the apical presence of R,S- and R-VPL, CsA and PSC 833 at similar concentrations described for single-cell suspensions, resulting in increased (2.2- to 3.7-fold) intracellular drug accumulation. Functional apical P-gp expression, the absence of paracellular leakage and modulator-sensitive rhodamine 123 efflux in single HCT-8 cells indicate a P-gp-mediated transcellular efflux in HCT-8 monolayers. In addition to its high MDR-reversing capacity, the inhibitory activity of PSC 833 is not affected by acidic extracellular conditions, which reduce the VPL-induced drug retention significantly. As far as MDR contributes to the overall cellular drug resistance of solid tumours with hypoxic and acidic microenvironments, PSC 833 holds the greatest promise for clinical reversal of unresponsiveness to the respective group of chemotherapeutics.

UI MeSH Term Description Entries
D007078 Ileal Neoplasms Tumors or cancer in the ILEUM region of the small intestine (INTESTINE, SMALL). Cancer of ILEUM,Cancer of the ILEUM,Cancer, Ileal,Ileal Cancer,Cancers, Ileal,ILEUM Cancer,ILEUM Cancers,Ileal Cancers,Ileal Neoplasm,Neoplasm, Ileal,Neoplasms, Ileal
D007080 Ileocecal Valve The valve, at the junction of the CECUM with the COLON, that guards the opening where the ILEUM enters the LARGE INTESTINE. Ileocecal Valves,Valve, Ileocecal,Valves, Ileocecal
D008562 Membrane Glycoproteins Glycoproteins found on the membrane or surface of cells. Cell Surface Glycoproteins,Surface Glycoproteins,Cell Surface Glycoprotein,Membrane Glycoprotein,Surface Glycoprotein,Glycoprotein, Cell Surface,Glycoprotein, Membrane,Glycoprotein, Surface,Glycoproteins, Cell Surface,Glycoproteins, Membrane,Glycoproteins, Surface,Surface Glycoprotein, Cell,Surface Glycoproteins, Cell
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D003524 Cyclosporins A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection. Cyclosporines
D003864 Depression, Chemical The decrease in a measurable parameter of a PHYSIOLOGICAL PROCESS, including cellular, microbial, and plant; immunological, cardiovascular, respiratory, reproductive, urinary, digestive, neural, musculoskeletal, ocular, and skin physiological processes; or METABOLIC PROCESS, including enzymatic and other pharmacological processes, by a drug or other chemical. Chemical Depression,Chemical Depressions,Depressions, Chemical
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J Zacherl, and G Hamilton, and T Thalhammer, and M Riegler, and E P Cosentini, and A Ellinger, and G Bischof, and M Schweitzer, and B Teleky, and T Koperna
November 1998, Japanese journal of cancer research : Gann,
J Zacherl, and G Hamilton, and T Thalhammer, and M Riegler, and E P Cosentini, and A Ellinger, and G Bischof, and M Schweitzer, and B Teleky, and T Koperna
October 1997, Anti-cancer drugs,
J Zacherl, and G Hamilton, and T Thalhammer, and M Riegler, and E P Cosentini, and A Ellinger, and G Bischof, and M Schweitzer, and B Teleky, and T Koperna
February 1992, International journal of cancer,
J Zacherl, and G Hamilton, and T Thalhammer, and M Riegler, and E P Cosentini, and A Ellinger, and G Bischof, and M Schweitzer, and B Teleky, and T Koperna
May 1999, Biochemical pharmacology,
J Zacherl, and G Hamilton, and T Thalhammer, and M Riegler, and E P Cosentini, and A Ellinger, and G Bischof, and M Schweitzer, and B Teleky, and T Koperna
August 1991, Cancer research,
J Zacherl, and G Hamilton, and T Thalhammer, and M Riegler, and E P Cosentini, and A Ellinger, and G Bischof, and M Schweitzer, and B Teleky, and T Koperna
January 1995, Oncology research,
J Zacherl, and G Hamilton, and T Thalhammer, and M Riegler, and E P Cosentini, and A Ellinger, and G Bischof, and M Schweitzer, and B Teleky, and T Koperna
October 1994, Biochemical pharmacology,
J Zacherl, and G Hamilton, and T Thalhammer, and M Riegler, and E P Cosentini, and A Ellinger, and G Bischof, and M Schweitzer, and B Teleky, and T Koperna
June 1995, British journal of haematology,
J Zacherl, and G Hamilton, and T Thalhammer, and M Riegler, and E P Cosentini, and A Ellinger, and G Bischof, and M Schweitzer, and B Teleky, and T Koperna
January 1997, Life sciences,
J Zacherl, and G Hamilton, and T Thalhammer, and M Riegler, and E P Cosentini, and A Ellinger, and G Bischof, and M Schweitzer, and B Teleky, and T Koperna
May 1998, International journal of cancer,
Copied contents to your clipboard!